Prognostic role of MicroRNA-21 in non-small cell lung cancer: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 2329-2334

  Ma, Xue Lei ^a   Liu, Lei ^a   Liu, Xiao Xiao ^a   Li, Yun ^b   Deng, Lei ^a   Xiao, Zhi Lan ^a   Liu, Yan Tong ^a   Shi, Hua Shan ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Lung cancer; Meta analysis; MicroRNA 21; Prognosis; Survival outcome

Indexed keywords

MICRORNA; MIRN21 MICRORNA, HUMAN;

ARTICLE; CANCER STAGING; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; META ANALYSIS; MORTALITY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MICRORNAS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84872675131     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.2329     Document Type: Article

References (33)

1. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-97.
2. Bartel DP, Chen CZ (2004). Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet, 5, 396-400.
3. Begg CB (1994). Publication bias. 299(409): 25.
4. Cornfield J (1951). A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix. J Natl Cancer Inst, 11, 1269-75.
5. de Planell-Saguer M, Rodicio MC (2011). Analytical aspects of microRNA in diagnostics: a review. Anal Chim Acta, 699, 134-52.
6. Diederichs S, Haber DA (2006). Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res, 66, 6097-104.
7. Gao W, Lu X, Liu L, et al (2012). MiRNA-21: A biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther, 13, 330-40.
8. Gao W, Shen H, Liu L, et al (2011). MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol, 137, 557-66.
9. Gao W, Xu J, Liu L, et al (2012). A systematic-analysis of predicted miR-21 targets identifies a signature for lung cancer. Biomed Pharmacother, 66, 21-8.
10. Gao W, Yu Y, Cao H, et al (2010). Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother, 64, 399-408.
11. Hatley ME, Patrick DM, Garcia MR, et al (2010). Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell, 18, 282-93.
12. Hayes DF, Isaacs C, Stearns V (2001). Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia, 6, 375-92.
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG. (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
14. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
15. Lawrie CH, Soneji S, Marafioti T, et al (2007). MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer, 121, 1156-61.
16. Liang Y (2008). An expression meta-analysis of predicted microRNA targets identifies a diagnostic signature for lung cancer. BMC Med Genomics, 1, 61.
17. Liu XG, Zhu WY, Huang YY, et al (2011). High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol, 29, 618-26.
18. Lu Z, Liu M, Stribinskis V, et al (2008). MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene, 27, 4373-9.
19. Markou A, Tsaroucha EG, Kaklamanis L, et al (2008). Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem, 54, 1696-704.
20. Nielsen BS, Jorgensen S, Fog JU, et al (2011). High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis, 28, 27-38.
21. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.
22. Qian B, Katsaros D, Lu L, et al (2009). High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat, 117, 131-40.
23. Ramalingam S, Pawlish K, Gadgeel S, Demers R, Kalemkerian GP (1998). Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. J Clin Oncol, 16, 651-7.
24. Saito M, Schetter AJ, Mollerup S, et al (2011). The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res, 17, 1875-82.
25. Siva AC, Nelson LJ, Fleischer CL, et al (2009). Molecular assays for the detection of microRNAs in prostate cancer. Mol Cancer, 8, 17.
26. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007). Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8, 16.
27. Voortman J, Goto A, Mendiboure J, et al (2010). MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res, 70, 8288-98.
28. Wang QZ, Xu W, Habib N, Xu R (2009). Potential uses of microRNA in lung cancer diagnosis, prognosis, and therapy. Curr Cancer Drug Targets, 9, 572-94.
29. Wang ZX, Bian HB, Wang JR, et al (2011). Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol, 104, 847-51.
30. Wei J, Gao W, Zhu CJ, et al (2011). Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer, 30, 407-14.
31. Williamson PR, Smith CT, Hutton JL, Marson AG (2002). Aggregate data meta-analysis with time-to-event outcomes. Stat Med, 21, 3337-51.
32. Yang CH, Yue J, Pfeffer SR, Handorf CR, Pfeffer LM (2011). MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J Biol Chem, 286, 39172-8.
33. Zhang JG, Wang JJ, Zhao F, et al (2010). MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta, 411, 846-52.